



Press Release

BioApex, s.r.o. signs Cooperative Research and Joint Commercialization Agreement with Palacký University, Olomouc, Czech Republic

Olomouc, Czech Republic (February 27, 2009) – BioApex, s.r.o., a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat serious cell cycle related disorders including various cancers, today announced that it has signed a cooperative research and joint commercialization agreement with the Palacký University. The cooperation will focus on the research, development and commercialisation of drugs combining anticancer and antiviral activities.

About BioApex, s.r.o.: BioApex owns a proprietary portfolio of small, second and third generation molecule-like compounds derived from plant hormones, emanating from the research of Prof. Miroslav Strnad and his team of scientists at the Laboratory of Growth Regulators in Olomouc, Czech Republic, that inhibit different kinases. Some of the kinases play a central role in the cell cycle, in the regulation of transcription and likely in many proliferative diseases. BioApex's intellectual property addresses the very broad fields of cell division related disorders and, besides cancers, includes restenosis, rheumatoid arthritis, glomerulonephritis, type I diabetes, multiple sclerosis, Alzheimer's disease, growth of parasites (animal, protists), graft rejection (host versus graft disease), graft versus host disease, gout and viral disorders. BioApex believes that, to date, there are no commercially available compounds that combine the same mode of action, effectiveness and minimal side effects.

BioApex plans to initially advance a group of promising compounds on which the design, *in vitro* testing and preclinical trials have been completed, to clinical testing. A second group of compounds will be taken through pharmacokinetic studies and pre-clinical efficacy trials to determine development priorities. BioApex's business model - a tiered strategy with some compounds in an advanced stage of development and encouraging results to date and some compounds in the pipeline for development – is tailored to attract both, industry "partners" and – in addition to governmental grants and loans - private equity to fund operations. With limited resources focused on research and development, BioApex plans to partner with strong pharmaceutical companies that have established sales and marketing channels in BioApex's target areas.

For more information, visit the company's website at www.bioapex.cz